|
Real-time Estimate
Cboe BZX
16:36:04 29/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1.120 USD | -4.27% |
|
-0.44% | -51.72% |
| 10-26 | Spero Therapeutics, Inc. Announces Executive Changes | CI |
| 08-12 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 68.13 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -48.1% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 68.13 | 68.13 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -48.1% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -2.02x | -11.1x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 28.3x | 1.67x | 0.75x | 1.17x | - | 264x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 264x | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | - | -1.86x | -1.24x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.58 | -0.105 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 18.26 | 53.51 | 103.8 | 47.98 | - | 0.258 | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT 1 | -87.97 | -42.2 | 21.48 | -73.36 | - | -36.66 | -55 |
| Net income 1 | -89.76 | -46.42 | 22.81 | -68.57 | - | -33.46 | -51.5 |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.170 | 1.170 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 31/03/22 | 30/03/23 | 13/03/24 | 27/03/25 | 26/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.02x | - | - | - | 68.13M | |
| 16.92x | 6.39x | 12.26x | 1.77% | 64.14B | |
| 30.57x | 8.11x | 26.59x | 0.05% | 55.53B | |
| 36.68x | 6.52x | 19.45x | 0.88% | 53.03B | |
| 35.39x | 3.41x | 14.74x | -.--% | 45.99B | |
| 49.25x | 5.68x | 31.09x | -.--% | 42.45B | |
| -19.59x | 189.6x | -20.86x | -.--% | 40.45B | |
| 31.7x | 8.06x | 20.96x | 0.41% | 32.25B | |
| 47.12x | 8.37x | 28.08x | -.--% | 34.47B | |
| 27.96x | 5.9x | 15.29x | -.--% | 24.23B | |
| Average | 25.40x | 26.89x | 16.40x | 0.34% | 39.26B | |
| Weighted average by Cap. | 27.96x | 25.38x | 16.46x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
